证券代码：000739 证券简称：普洛药业 公告编号：2024-52 普洛药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司（以下简称"康裕制药"）收到国家药品监督管理局（以下简称 "药监局"）下发的盐酸安非他酮缓释片（Ⅱ）《药品补充申请批准通知书》。 现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：盐酸安非他酮缓释片（Ⅱ） 2、剂型：片剂 3、规格：150mg 4、补充申请事项：新增 150mg 规格 5、上市许可持有人：浙江普洛康裕制药有限公司 6、通知书编号：2024B05020 7、药品批准文号：国药准字 H20247260 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品此次申请事项符合药品注册的有关要求，批准本品新增 150mg 规格的补充 申请事项，发给药品批准文号。 二、药品其他相关情况 盐酸安非他酮缓释片（II）用于治疗抑郁症。根据相关数据显示，盐酸安非 他酮口服剂型在国内 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [4][10] Core Views - The company has shown steady revenue growth with a significant improvement in the gross margin of its formulation segment. The revenue for the first three quarters of 2024 reached 9.29 billion yuan, an increase of 9.3% year-on-year, while the net profit attributable to the parent company was 870 million yuan, up 2.2% year-on-year [5][10] - The report highlights the strong performance of the formulation segment, while the CDMO segment experienced a decline in revenue due to a high base effect from the previous year. The raw material segment achieved revenue of 6.90 billion yuan, a year-on-year increase of 15.3%, while the CDMO segment's revenue was 1.42 billion yuan, down 11.4% year-on-year [5][9] - The company is experiencing a high growth rate in its CDMO business, with the number of quoted projects increasing by 85% year-on-year to 1,198 projects, and ongoing projects rising by 47% to 948 projects [2][9] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 9.29 billion yuan (+9.3%), with a net profit of 870 million yuan (+2.2%) and a non-recurring net profit of 830 million yuan (+0.4%). In Q3 alone, revenue was 2.86 billion yuan (+12.4%), while net profit was 240 million yuan (-2.2%) [5][10] - The gross margin for the formulation segment improved significantly to 62.2%, an increase of nearly 10 percentage points year-on-year, attributed to adjustments in sales models and improved production efficiency [5][9] Segment Performance - Raw Material Segment: Revenue of 6.90 billion yuan (+15.3%), gross profit of 1.08 billion yuan (-0.9%), gross margin of 15.6% (-2.6 percentage points) [5][9] - CDMO Segment: Revenue of 1.42 billion yuan (-11.4%), gross profit of 580 million yuan (-19.6%), gross margin of 40.8% (-4.2 percentage points) [5][9] - Formulation Segment: Revenue of 950 million yuan (+8.6%), gross profit of 590 million yuan (+28.0%), gross margin of 62.2% [5][9] Future Outlook - The company maintains its profit forecast, expecting net profits of 1.123 billion yuan, 1.325 billion yuan, and 1.594 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 6.4%, 18.0%, and 20.3% [10][12]

证券代码：000739 证券简称：普洛药业 公告编号：2024-51 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2024 年 10 月 29 日，普洛药业股份有限公司（以下简称"公司"）与中 国农业银行股份有限公司东阳市支行（以下简称"农业银行"）签订《保证合同》 （合同编号：33100120240015952），同意为公司控股子公司浙江普洛康裕制药 有限公司（以下简称"康裕制药"）与农业银行签署的《商业汇票银行承兑合同》 （合同编号：33180120240018143）中的 1,683.76 万元银行承兑汇票提供连带责 任保证，担保期限 6 个月。 2、2024 年 10 月 30 日，公司与中国进出口银行浙江省分行（以下简称"进 出口银行"）签订《保证合同》[合同编号：（2024）进出银（浙信保）字第 3-017 号]，同意为公司全资子公司浙江普洛家园药业有限公司（以下简称"家园药业"） 与进出口银行签署的《借款合同（出口卖方信贷）》[合同编号：（2024）进出 银（浙信合）字 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Views - The company has shown stable revenue growth with a 9.30% increase in revenue to 9.29 billion yuan for Q1-Q3 2024, and a 2.15% increase in net profit to 870 million yuan. Q3 revenue reached 2.86 billion yuan, up 12.41%, while net profit decreased by 2.21% due to foreign exchange losses [1][2] - The gross margin is under short-term pressure, with a gross margin of 24.23% for Q1-Q3 2024, down 2.55 percentage points year-on-year. The Q3 gross margin was 23.18%, down 4.02 percentage points year-on-year, primarily due to high base prices of raw materials in the same period last year and an increase in low-margin foreign trade products [1][2] - The company is expanding its project and customer base, with a significant increase in CDMO projects and ongoing projects. As of H1 2024, the company has registered two API varieties and submitted 20 new DMF applications, with a 51% year-on-year increase in CDMO project quotes [1][2] Financial Summary - For the financial year 2024E, the company forecasts revenue of 12.66 billion yuan, a 10.4% increase, and a net profit of 1.15 billion yuan, an 8.8% increase. The EPS is projected to be 0.98 yuan for 2024, 1.15 yuan for 2025, and 1.42 yuan for 2026 [7][8] - The company’s total assets are projected to reach 14.79 billion yuan by 2024, with total liabilities of 7.93 billion yuan, resulting in a net asset value of 6.85 billion yuan [8]

编号：2024-05 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in Q3 met expectations, with stable revenue growth during the off-peak season. The revenue for the first three quarters reached 10.54 billion yuan, a year-on-year increase of 17.92% [1] - The growth in revenue is primarily driven by the rapid expansion of the formulation segment due to centralized procurement, along with an increasing market share of core API products and a growing number of clients and projects in the CDMO business [1][2] - The company is expected to maintain robust growth in revenue and profit, with projected net profits of 1.14 billion yuan for 2023, reflecting a year-on-year growth of 7.90% [1][2] Financial Performance Summary - **Revenue (Million Yuan)**: - 2022A: 10,544.91 - 2023A: 11,474.16 (YoY growth: 8.81%) - 2024E: 12,716.23 (YoY growth: 10.82%) - 2025E: 14,004.28 (YoY growth: 10.13%) - 2026E: 15,477.21 (YoY growth: 10.52%) [1] - **Net Profit (Million Yuan)**: - 2022A: 989.17 - 2023A: 1,055.34 (YoY growth: 6.69%) - 2024E: 1,138.72 (YoY growth: 7.90%) - 2025E: 1,271.50 (YoY growth: 11.66%) - 2026E: 1,478.92 (YoY growth: 16.31%) [1] - **Earnings Per Share (Yuan)**: - 2022A: 0.84 - 2023A: 0.90 - 2024E: 0.97 - 2025E: 1.08 - 2026E: 1.25 [1] - **Market Capitalization (Million Yuan)**: - As of October 17, 2024, the market capitalization is 18,896.27 [1] Quarterly Financial Data - **Q1-Q3 2024 Revenue**: 9,290.22 million yuan, a year-on-year increase of 9.30% [2] - **Q1-Q3 2024 Net Profit**: 869.65 million yuan, a year-on-year increase of 2.15% [2] - **Operating Cash Flow**: 1,165.71 million yuan, a year-on-year increase of 37.38% [2] Future Outlook - The company is expected to continue its growth trajectory, with revenue projected to reach 12.72 billion yuan in 2024 and net profit expected to grow to 1.14 billion yuan [1][2] - The company maintains a strong competitive position in the industry, supported by its diversified business strategy and continuous improvement in operational efficiency [1][2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 9.29 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 9.30%, with a net profit attributable to shareholders of 870 million yuan, up 2.15% [2] - In Q3 alone, the company achieved a revenue of 2.862 billion yuan, an increase of 12.41%, while the net profit attributable to shareholders was 245 million yuan, down 2.19% [2] - The significant decrease in sales expense ratio is attributed to enhanced cost control and optimized market strategies, while the increase in financial expenses is mainly due to exchange losses [2] - The company is progressing well in integrated development, with over 25 formulation projects initiated annually, and is expected to see growth in related products by 2025 [2] - The profit forecast for 2024-2026 has been adjusted to 11.9 billion, 13.8 billion, and 15.6 billion yuan respectively, with a current market value corresponding to P/E valuations of 16, 14, and 12 times [2] Summary by Sections Financial Performance - Total revenue for 2022 was 10.545 billion yuan, with a year-on-year growth of 17.92%, and for 2023, it was 11.474 billion yuan, with a growth of 8.81% [1] - The net profit attributable to shareholders for 2022 was 989.17 million yuan, with a growth of 3.52%, and for 2023, it was 1,055.34 million yuan, with a growth of 6.69% [1] - The latest diluted EPS for 2024 is projected to be 1.02 yuan per share, with a P/E ratio of 15.69 [1] Cost Management - The sales expense ratio for Q3 was 4.16%, down 2.2 percentage points, while the management expense ratio was 4.54%, up 0.06 percentage points [2] - The R&D expense ratio was 5.31%, up 0.13 percentage points, and the financial expense ratio was 1.12%, up 1.86 percentage points due to exchange losses [2] Strategic Development - The company is enhancing its technical platforms and has signed a strategic cooperation framework agreement to strengthen its capabilities in synthetic biology and enzyme catalysis [2] - The integrated development strategy is expected to support the growth of the company's various business segments [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][11]. Core Views - The company achieved steady revenue growth in the first three quarters of 2024, with revenue reaching 9.29 billion yuan (up 9.3% year-on-year) and net profit attributable to shareholders of 870 million yuan (up 2.15% year-on-year) [3]. - The company has signed a strategic cooperation agreement with Baikuirui to enhance its research and production capabilities in protein and peptide drugs [5]. Financial Performance Summary - For the first three quarters of 2024, the company reported: - Revenue: 9.29 billion yuan (up 9.3%) - Net profit: 870 million yuan (up 2.15%) - Non-recurring net profit: 831 million yuan (up 0.4%) - Gross margin: 24.23% (down 2.55 percentage points) - Net margin: 9.36% (down 0.66 percentage points) [3]. - In Q3 2024, the company recorded: - Revenue: 2.862 billion yuan (up 12.41%) - Net profit: 245 million yuan (down 2.19%) - Non-recurring net profit: 229 million yuan (down 1.75%) - Gross margin: 23.18% (down 4.02 percentage points) - Net margin: 8.55% (down 1.28 percentage points) [3]. - The company maintains its profit forecast, expecting net profits of 1.238 billion yuan, 1.462 billion yuan, and 1.700 billion yuan for 2024, 2025, and 2026 respectively, with current price-to-earnings ratios of 15.3, 12.9, and 11.1 times [3]. Financial Ratios and Projections - Key financial metrics for 2024E: - Revenue: 13.029 billion yuan (up 13.6%) - Net profit: 1.238 billion yuan (up 17.3%) - Gross margin: 26.0% - Net margin: 9.5% - Return on equity (ROE): 17.5% - Earnings per share (EPS): 1.06 yuan [6]. - The company’s financial expenses increased by 74 million yuan year-on-year due to exchange losses, compared to exchange gains in the same period last year [4].

Financial Performance - Revenue for the third quarter of 2024 was RMB 2,861,505,455.47, an increase of 12.41% year-over-year[2] - Net profit attributable to shareholders for the third quarter was RMB 244,809,564.16, a decrease of 2.19% year-over-year[2] - Operating revenue reached 9,290,220,207.76 RMB, an increase from 8,500,085,529.08 RMB in the same period last year[12] - Operating costs totaled 8,295,069,270.45 RMB, up from 7,444,588,905.92 RMB[12] - Net profit attributable to the parent company's owners was 5,026,026,552.02 RMB, up from 4,520,034,984.41 RMB[11] - Operating profit for the quarter reached 1,023,122,464.97 yuan, a slight increase from 1,013,524,987.41 yuan in the previous period[13] - Net profit attributable to the parent company's shareholders was 869,652,417.71 yuan, up from 851,344,083.86 yuan in the prior period[13] - Sales revenue from goods and services reached 7,470,804,774.82 yuan, a significant rise from 5,986,375,397.51 yuan in the same period last year[14] - Basic earnings per share increased to 0.7466 yuan from 0.7281 yuan in the previous period[13] - Comprehensive income attributable to the parent company's shareholders rose to 873,223,790.05 yuan, compared to 848,248,390.43 yuan in the prior period[13] Cash Flow and Liquidity - Operating cash flow for the first nine months of 2024 was RMB 1,165,709,114.84, an increase of 37.38% year-over-year[2] - Net cash flow from financing activities was RMB -532,530,690.54, a decrease of 72.15% year-over-year, mainly due to increased stock repurchases and dividend payments[5] - Cash flow from operating activities increased to 1,165,709,114.84 yuan, compared to 848,540,440.86 yuan in the previous year[15] - Cash received from tax refunds amounted to 377,272,002.48 yuan, slightly higher than 366,708,211.74 yuan in the previous year[15] - Cash paid for goods and services increased to 5,241,010,944.55 yuan, up from 4,197,997,038.54 yuan in the prior period[15] - Cash flow from investment activities showed a net outflow of 364,538,076.21 yuan, an improvement from a net outflow of 460,801,711.33 yuan in the previous year[15] - Cash and cash equivalents at the end of the period stood at 2,735,557,535.96 yuan, up from 2,495,464,491.45 yuan at the beginning of the period[16] Assets and Liabilities - Total assets as of the end of the third quarter were RMB 13,339,366,342.08, an increase of 4.48% compared to the end of the previous year[2] - Total assets increased to 13,339,366,342.08 RMB, up from 12,767,664,072.34 RMB in the previous period[10] - Total liabilities rose to 6,751,589,006.48 RMB, compared to 6,537,246,876.10 RMB previously[10] - Owner's equity grew to 6,587,777,335.60 RMB, up from 6,230,417,196.24 RMB[11] - The company's monetary funds increased to 3,892,828,335.80 RMB at the end of the period, up from 3,580,686,915.36 RMB at the beginning of the period[9] - Accounts receivable rose to 1,762,610,761.91 RMB, compared to 1,695,032,971.13 RMB at the start of the period[9] - Inventory decreased to 1,844,380,687.82 RMB from 2,083,301,418.08 RMB at the beginning of the period[9] - Fixed assets stood at 2,866,856,667.27 RMB, down from 3,001,108,252.13 RMB at the start of the period[9] - Construction in progress increased to 767,150,754.39 RMB, up from 545,846,228.04 RMB at the beginning of the period[9] - Short-term borrowings increased to 871,965,120.77 RMB, compared to 807,796,237.52 RMB[10] - Accounts payable and advances from customers totaled 1,969,400,370.43 RMB, down from 2,013,890,900.04 RMB[10] - Intangible assets decreased to 312,410,959.01 RMB, from 319,795,853.83 RMB[10] R&D and Investments - R&D investment for the first nine months of 2024 was RMB 467,201,967.23, an increase of 5.26% year-over-year[5] - R&D expenses amounted to 467,201,967.23 RMB, a decrease from 483,755,349.59 RMB[12] - Prepayments increased by 119.94% year-over-year to RMB 565,176,702.21, mainly due to increased prepayments for materials[5] - Other non-current assets increased by 191.79% year-over-year to RMB 156,849,038.35, primarily due to increased prepayments for equipment[5] Shareholder Information - The company repurchased 10,880,000 shares, representing 0.93% of the total shares, through a dedicated securities account[7] - Hengdian Group Holding Co., Ltd. holds 28.30% of the company's shares, totaling 330,941,729 shares[7] - Zhejiang Hengdian Import & Export Co., Ltd. holds 13.39% of the company's shares, totaling 156,552,903 shares[7] - Zhejiang Hengrun Technology Co., Ltd. holds 5.10% of the company's shares, totaling 59,683,845 shares[7] - Hengdian Group Jiayuan Chemical Co., Ltd. holds 3.83% of the company's shares, totaling 44,750,178 shares[7] Government Subsidies and Returns - Government subsidies received during the third quarter amounted to RMB 19,784,103.27[3] - The weighted average return on equity for the first nine months of 2024 was 13.52%, a decrease of 1.25 percentage points year-over-year[2]

证券代码：000739 证券简称：普洛药业 公告编号：2024-49 普洛药业股份有限公司 关于盐酸金刚烷胺片获得美国 FDA 上市批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 4.ANDA 号：218598 5.适应症：用于预防和治疗由甲型流感病毒感染引起的体征和症状。也可用 于治疗帕金森病及各种帕金森综合征（例如脑炎后帕金森综合征、血管性帕金森 综合征和一氧化碳中毒性帕金森综合征）。还可以用于治疗药物引起的锥体外系 反应。 6.申请人：浙江巨泰药业有限公司 7.生产企业：浙江普洛康裕制药有限公司 近日，普洛药业股份有限公司（以下简称"公司"）之全资子公司浙江巨泰 药业有限公司收到美国食品药品监督管理局（以下简称"美国 FDA"）签发的盐 酸金刚烷胺片 100mg（ANDA 号：218598）的批准信。现将相关情况公告如下： 一、药品基本情况 1.药品名称：盐酸金刚烷胺片 2.剂型：片剂 3.规格：100mg 二、药品其他相关情况 金刚烷胺主要机制是促进纹状体多巴胺的合成和释放，减少神经细胞对多巴 胺的再摄取，并有抗乙酰胆碱作用。同时作为临床非 ...